Researchers descover melanoma-promoting gene

Until recently, it was assumed that a tumor was composed of many equivalent cells that all multiply malignantly and can thus contribute towards tumor growth. According to a more recent hypothesis, however, a tumor might also consist of malignant cancer stem cells and other less aggressive tumor cells. Normally, stem cells are responsible for the formation of organs. Cancer stem cells can divide in a very similar way and develop into other tumor cells to form the tumor. Efficient tumor therapy thus primarily needs to fight cancer stem cells. Consequently, a team of stem-cell researchers from the University of Zurich headed by Professor Sommer decided to find out whether mechanisms that are important for normal stem cells also play a role in cancer stem cells.  

Melanoma cells are rogue skin-pigment cells formed by so-called neural crest stem cells during embryonic development. Professor Sommer’s group teamed up with dermatologists and pathologists to investigate whether cells with characteristics of these specific stem cells are present in human tumor tissue. “This was indeed the case, as we were able to prove based on numerous biopsies performed on melanoma patients,” says Sommer. In particular, one gene that effectively controls the stem-cell program was highly active in all the tumor tissue studied. This gene, which is known as “Sox10”, is essential for cell division and the survival of stem cells.

The next step for the Zurich researchers was to test how Sox10 works in human melanoma cells. They determined that the gene also controls a stem-cell program in cancer cells and is necessary for cell division. In order to corroborate these findings in a living organism, the researchers ultimately used a mouse which carried similar genetic mutations to those found in human melanoma and thus developed black skin cancer spontaneously. Astonishingly, the suppression of Sox10 in this animal model completely inhibited the formation and spread of cancer.

“Our research demonstrates that a tumor could probably be treated by attacking its stem cells,” concludes Sommer. The results also illustrate that such studies can primarily be successful through the close collaboration and conscious use of synergies between basic researchers and clinicians.

Provided by University of Zurich